Piper Jaffray analyst Kevin Ellich reiterated an Overweight rating on Parnell Pharmaceuticals (NASDAQ: PARN) but trimmed his price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE